Low Density Lipoprotein MDA Modified

<strong>Low Density Lipoprotein MDA Modified</strong>_x000D_ <strong>Catalog number:</strong> B2012263_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 1 mg/mL_x000D_ <strong>Supplied as:</strong> Liquid_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> MDA modified LDL_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Tikhaze AK, Domogatsky SP, Lankin VZ. [Elimination kinetics of carbonyl-modified low density lipoproteins from bloodstream] Biomed Khim. 2020 Nov;66(6):437-443._x000D_ 2: Yokoi M, Ito T, Fujita H, Sugiura T, Seo Y, Ohte N. Increased Serum Malondialdehyde-Modified Low-Density Lipoprotein and Coronary Angiographic Progression After Drug-Eluting Stent Implantation in Patients With Stable Angina Circ J. 2020 Sep 25;84(10):1837-1845._x000D_ 3: Takamura TA, Tsuchiya T, Oda M, Watanabe M, Saito R, Sato-Ishida R, Akao H, Kawai Y, Kitayama M, Kajinami K. Circulating malondialdehyde-modified low-density lipoprotein (MDA-LDL) as a novel predictor of clinical outcome after endovascular therapy in patients with peripheral artery disease (PAD) Atherosclerosis. 2017 Aug;263:192-197._x000D_ 4: Ito T, Fujita H, Tani T, Sugiura T, Ohte N. Increased circulating malondialdehyde-modified low-density lipoprotein levels in patients with ergonovine-induced coronary artery spasm Ito T, Fujita H, Tani T, Sugiura T, Ohte N._x000D_ 5: Ohira M, Yamaguchi T, Saiki A, Ban N, Kawana H, Nagayama D, Nagumo A, Murano T, Shirai K, Tatsuno I. Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus Clin Invest Med. 2014 Aug 1;37(4):E243-51._x000D_ 6: Amioka N, Miyoshi T, Otsuka H, Yamada D, Takaishi A, Ueeda M, Hirohata S, Ito H. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention J Cardiol. 2019 Sep;74(3):258-266._x000D_ 7: Hiraya D, Sato A, Hoshi T, Sakai S, Watabe H, Ieda M. Additional Effect of Coronary High-Intensity Plaque on T1-Weighted Magnetic Resonance Imaging With Circulating Malondialdehyde-Modified Low-Density Lipoprotein on Cardiac Events Circ J. 2021 Oct 25;85(11):2032-2039._x000D_ 8: Moriyama K. The Association between the Triglyceride to High-density Lipoprotein Cholesterol Ratio and Low-density Lipoprotein Subclasses Intern Med. 2020 Nov 1;59(21):2661-2669._x000D_ 9: Turunen SP, Kummu O, Wang C, Harila K, Mattila R, Sahlman M, Pussinen PJ, Hörkkö S. Immunization with malondialdehyde-modified low-density lipoprotein (LDL) reduces atherosclerosis in LDL receptor-deficient mice challenged with Porphyromonas gingivalis Innate Immun. 2015 May;21(4):370-85._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/29067491">10: Ito T, Ichihashi T, Fujita H, Sugiura T, Ohte N. Impact of malondialdehyde-modified low-density lipoprotein on coronary plaque vulnerability in patients not receiving lipid-lowering therapy: a whole coronary analysis with multislice-computed tomography Heart Vessels. 2018 Apr;33(4):351-357. </a>_x000D_ _x000D_ <strong>Products Related to Low Density Lipoprotein MDA Modified can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>